Macrophage Pharma Seeks Funding To Take Novel Cancer Therapy Forward
CEO Says Money Would Fund Lead Asset’s Clinical Development
Executive Summary
Macrophage Pharma’s lead asset will advance to clinical trials next year, making a series B financing round necessary, the UK biotech’s CEO tells Scrip.
You may also be interested in...
Patient-Centric: Evotec’s CSO Explains R&D Strategy
Evotec’s multimodality approach to drug discovery landed the biotech two new discovery collaborations this week, underscoring its emphasis on patient-driven data.
Novo Nordisk, Evotec Link Around Chronic Kidney Disease
Novo Nordisk and Evotec will identify and develop novel drugs for treating chronic kidney disease, using datasets of CKD patients provided by the Danish group and from other sources.
Strategic M&A: Sanofi Buys Principia Biopharma For $3.7bn
Sanofi is paying for $3.68bn cash for Principia to get the US biotech’s drug development platform and nascent pipeline, including a brain-penetrant BTK inhibitor in Phase III for multiple sclerosis.
Need a specific report? 1000+ reports available
Buy Reports